CPH · NOVO-B.CO
Novo Nordisk A/S
DKK 260.35+DKK 5.35 (+2.1%)
Novo Nordisk A/S’s quoted price sits in the lower half of its reported 52-week range, 36.49% below the high.
Loading market information…
CPH · BAVA.CO · DKK
Stock price, earnings
Quote as of Oct 29, 2026, 03:59 PM UTC. Cached market data; not a live quote.
One-year closing-price history · DKK. Historical prices are not a forecast.
Bavarian Nordic A/S’s quoted price sits in the upper half of its reported 52-week range, 3.58% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Bavarian Nordic A/S’s next earnings report is currently expected on Nov 13, 2026, with estimated earnings per share of DKK 5.30. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Bavarian Nordic A/S’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Hellerup, Denmark-based Bavarian Nordic A/S, founded in 1992, specializes in the research, production, and global distribution of vital, life-saving vaccines. The company's commercialized offerings include non-replicating vaccines for smallpox and monkeypox, marketed as IMVAMUNE, IMVANEX, and JYNNEOS. Additionally, their portfolio features Rabipur/RabAvert for rabies prevention, Encepur for tick-borne encephalitis, and MVABEA, an Ebola vaccine. Bavarian Nordic also maintains a robust pipeline of investigational treatments. This includes MVA-BN (freeze-dried), which has successfully completed Phase III clinical trials for smallpox; MVA-BN RSV, currently in Phase III development for respiratory syncytial virus; ABNCoV2, which completed Phase II trials targeting SARS-CoV-2; and TAEK-VAC, presently in Phase I/II trials for advanced HER2 and brachyury-expressing cancers. The firm engages in key partnerships, notably a license and collaboration agreement with AdaptVac, and licensing agreements with both the National Cancer Institute and the Public Health Service. Bavarian Nordic operates across a wide international footprint, with a presence in countries such as the United States, Germany, Belgium, France, Canada, the United Kingdom, Hong Kong, Saudi Arabia, Australia, Switzerland, and numerous other global markets.
Latest available per-share figures in DKK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:56 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 8, 2025 | DKK 2.70 | DKK 1.35B+35.56% vs estimate |
|---|
| Q4 2024 | Mar 5, 2025 | DKK 9.81+14.6% vs estimate | DKK 2.09B+11.85% vs estimate |
|---|
| Q3 2024 | Nov 15, 2024 | DKK 0.90-82.73% vs estimate | DKK 1.41B-16.31% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
DKK 260.35+DKK 5.35 (+2.1%)
Novo Nordisk A/S’s quoted price sits in the lower half of its reported 52-week range, 36.49% below the high.
DKK 3,788.00-DKK 80.00 (-2.07%)
Genmab A/S’s quoted price sits in the upper half of its reported 52-week range, 3.49% below the high.
$253.00+$3.45 (+1.38%)
Ascendis Pharma A/S’s quoted price sits in the upper half of its reported 52-week range, 10.33% below the high.
DKK 477.00-DKK 1.50 (-0.31%)
Coloplast A/S’s quoted price sits in the lower half of its reported 52-week range, 24.45% below the high.
DKK 366.00+DKK 3.20 (+0.88%)
Demant A/S’s quoted price sits in the upper half of its reported 52-week range, 0.81% below the high.
DKK 246.60+DKK 3.00 (+1.23%)
ALK-Abelló A/S’s quoted price sits in the upper half of its reported 52-week range, 9.14% below the high.
DKK 54.45+DKK 1.65 (+3.13%)
H. Lundbeck A/S’s quoted price sits in the upper half of its reported 52-week range, 0.64% below the high.
DKK 78.60-DKK 1.40 (-1.75%)
Ambu A/S’s quoted price sits in the lower half of its reported 52-week range, 24.86% below the high.
